Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer

M K Boisen, J S Johansen, Christian Dehlendorff, J S Larsen, K Osterlind, J Hansen, S E Nielsen, P Pfeiffer, Line Schmidt Tarpgaard, N H Holländer, N Keldsen, T F Hansen, B B Jensen, B V Jensen

Publikation: Bidrag til tidsskriftTidsskriftartikel

Abstrakt

There is an unmet need for predictive markers for the antiangiogenic agent bevacizumab in metastatic colorectal cancer (mCRC). We aimed to assess whether the location of the primary tumor is associated with bevacizumab effectiveness when combined with capecitabine and oxaliplatin (CAPEOX) in the first-line treatment of patients with mCRC.
OriginalsprogEngelsk
TidsskriftAnnals of Oncology
Vol/bind24
Udgave nummer10
Sider (fra-til)2554-2559
ISSN0923-7534
DOI
StatusUdgivet - okt. 2013

Fingeraftryk Dyk ned i forskningsemnerne om 'Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer'. Sammen danner de et unikt fingeraftryk.

  • Citationsformater

    Boisen, M. K., Johansen, J. S., Dehlendorff, C., Larsen, J. S., Osterlind, K., Hansen, J., Nielsen, S. E., Pfeiffer, P., Tarpgaard, L. S., Holländer, N. H., Keldsen, N., Hansen, T. F., Jensen, B. B., & Jensen, B. V. (2013). Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Annals of Oncology, 24(10), 2554-2559. https://doi.org/10.1093/annonc/mdt253